Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MIF antisense RNA 1 (MIF-AS1) is a long non-coding antisense RNA, located on chromosome 21 or possibly 22 (some sources disagree), with emerging evidence of a critical role in regulating gene expression in cancer and inflammatory contexts[1]. MIF-AS1 acts as a molecular sponge for microRNAs such as miR-212-5p, thereby upregulating target genes like NDUFA4, which promote tumor cell proliferation and suppress apoptosis by modulating mitochondrial oxidative phosphorylation[3]. Its expression is notably increased in certain cancers, including gastric cancer. MIF-AS1 exemplifies the significance of lncRNAs as regulators of key biological processes and as potential therapeutic targets, though no clinical drugs directly target it yet. The molecule is under active study as both a biomarker and a molecular target due to its influence on cellular pathways central to disease progression[1][3][5].
Molecular sponge for microRNAs (miR-212-5p, miR-29a-3p) that regulate genes such as NDUFA4. Competitive endogenous RNA (ceRNA) function, modulating mRNA stability and translation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MIF antisense RNA 1 (MIF-AS1).